Compare SAMG & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SAMG | SGMO |
|---|---|---|
| Founded | 2002 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.5M | 141.2M |
| IPO Year | 2012 | 2000 |
| Metric | SAMG | SGMO |
|---|---|---|
| Price | $15.23 | $0.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | 29.2K | ★ 7.7M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 5.54% | N/A |
| EPS Growth | N/A | ★ 66.89 |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $91,358,000.00 | $36,567,000.00 |
| Revenue This Year | $3.37 | $4.79 |
| Revenue Next Year | $10.62 | N/A |
| P/E Ratio | $27.78 | ★ N/A |
| Revenue Growth | N/A | ★ 88.60 |
| 52 Week Low | $13.23 | $0.35 |
| 52 Week High | $18.60 | $1.06 |
| Indicator | SAMG | SGMO |
|---|---|---|
| Relative Strength Index (RSI) | 53.67 | 48.66 |
| Support Level | $14.74 | $0.35 |
| Resistance Level | $15.41 | $0.56 |
| Average True Range (ATR) | 0.33 | 0.03 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 78.99 | 63.33 |
Silvercrest Asset Management Group Inc is a wealth management firm focused on providing financial advisory and related family office services to ultra-high net-worth individuals and institutional investors. It advises clients on traditional investment strategies focused on equities, fixed income and cash as well as non-traditional investment strategies including hedge funds, private equity funds, real estate and commodities. It also provides clients with family office services and related administrative services, which include financial planning, tax planning and preparation, partnership accounting and fund administration, and consolidated wealth reporting. The company derives revenues principally from assets under management.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.